TNB Tech Minute: FDA Reverses Rejection of Another Rare-Disease Drug

**SPEAKER_1** (0:00)
Many companies are struggling to scale their AI deployments or even move them past the pilot stage. Often the problem isn't technology, but organizational misalignment around goals, processes, and incentives. At the break, join Caroline Roach, a senior partner, IBM Consulting, to learn why.

**Danny Lewis** (0:16)
Here's your morning TNB Tech Minute for Monday, June 22nd. I'm Danny Lewis for The Wall Street Journal. We exclusively report that biotech company RegenX Bio says the US Food and Drug Administration has agreed to reverse its rejection of an experimental gene therapy. The therapy targets Hunter syndrome, a rare, fatal genetic disease that causes irreversible brain damage and cell death. The about face is the latest by the agency that's under new leadership, and marks a broader retreat from demands that rare disease drug makers test their experimental medicines against placebos to make sure the drugs work. After filing an appeal, RegenX Bio says the FDA indicated it would drop demands for the new study. The FDA did not respond to a request for comment.
Chevron has struck a 20-year agreement to sell electricity to Microsoft to power what could become one of the country's largest AI data centers. The oil company is working with energy company Julant to supply the West Texas data center with natural gas produced in the area. The companies didn't disclose a cost estimate for the project. The data center will have its own on-site power plant instead of being plugged into the Texas grid, but will connect to the grid at a later date to sell excess electricity into the power market. The deal cements Chevron's lead in the race among major oil companies to bank on the data center boom.
And a Chinese robotics company backed by SoftBank group is gearing up to go public in Hong Kong. People familiar with the matter say Kuwa plans to file the initial public offering application within the next two to three months. They say its valuation stood at more than $3 billion after it raised more than $600 million in its latest funding round. The people said the company is working with Huatai Securities and Deutsche Bank on the listing. Kuwa develops embodied AI robots for urban environments and sectors including shared mobility, manufacturing and property services.
That's your TNB Tech Minute. Join us again this afternoon for more.

**SPEAKER_1** (2:09)
Scaling AI successfully requires more than the right technology. Here again is Caroline Roach, Senior Partner, IBM Consulting.

**Caroline Roach** (2:16)
The biggest thing that we were talking about a year ago is what model to use. And the biggest thing that I'm talking about with my clients now is how do I drive change within my organization.

**SPEAKER_1** (2:28)
Companies able to identify correct and then avoid misalignment will be best positioned to deliver meaningful business value from AI.

**Caroline Roach** (2:34)
The organizations that are the most successful set very clear targets and have several priorities that are very clear across the enterprise. The technology is really good, but if you're not changing your organizational alignment, not incentivizing your people correctly, not looking at workflows, you're not going to see real value with it.

**SPEAKER_1** (2:55)
Visit ibm.com/think/leadership to learn how building organizational alignment can help deliver AI deployments that scale and drive growth.

**SPEAKER_4** (3:03)
This content was created by Custom Content from WSJ, a unit of the Wall Street Journal Advertising Department.